CN104884095A - Cart19用于耗减正常b细胞以诱导耐受的用途 - Google Patents

Cart19用于耗减正常b细胞以诱导耐受的用途 Download PDF

Info

Publication number
CN104884095A
CN104884095A CN201380037500.6A CN201380037500A CN104884095A CN 104884095 A CN104884095 A CN 104884095A CN 201380037500 A CN201380037500 A CN 201380037500A CN 104884095 A CN104884095 A CN 104884095A
Authority
CN
China
Prior art keywords
cells
cell
car
cart19
genetically engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380037500.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·L·莱文
M·D·卡罗斯
C·H·琼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Priority to CN202510240499.1A priority Critical patent/CN120393001A/zh
Publication of CN104884095A publication Critical patent/CN104884095A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380037500.6A 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途 Pending CN104884095A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510240499.1A CN120393001A (zh) 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261671508P 2012-07-13 2012-07-13
US61/671,508 2012-07-13
PCT/US2013/050293 WO2014012001A2 (en) 2012-07-13 2013-07-12 Use of cart19 to deplete normal b cells to induce tolerance

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510240499.1A Division CN120393001A (zh) 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途

Publications (1)

Publication Number Publication Date
CN104884095A true CN104884095A (zh) 2015-09-02

Family

ID=49916701

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380037500.6A Pending CN104884095A (zh) 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途
CN202510240499.1A Pending CN120393001A (zh) 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510240499.1A Pending CN120393001A (zh) 2012-07-13 2013-07-12 Cart19用于耗减正常b细胞以诱导耐受的用途

Country Status (13)

Country Link
US (3) US20150290244A1 (2)
EP (1) EP2872184B1 (2)
JP (5) JP2015523386A (2)
KR (1) KR102216083B1 (2)
CN (2) CN104884095A (2)
AU (3) AU2013289984B2 (2)
BR (1) BR112015000657B1 (2)
CA (1) CA2876734A1 (2)
EA (2) EA201992742A3 (2)
ES (1) ES2835232T3 (2)
IN (1) IN2015DN00139A (2)
MX (2) MX382772B (2)
WO (1) WO2014012001A2 (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109328230A (zh) * 2016-04-15 2019-02-12 宾夕法尼亚大学董事会 嵌合同种异体抗原受体t细胞的组合物和方法
WO2021129015A1 (zh) * 2019-12-27 2021-07-01 昭泰英基生物医药（香港）有限公司 工程化免疫杀伤细胞、其制备方法和应用

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US20150290244A1 (en) * 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance
US9573988B2 (en) 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
JP6647868B2 (ja) 2013-02-20 2020-02-14 ノバルティス アーゲー ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
AU2015244039B2 (en) * 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
CA2946312A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
WO2016028879A1 (en) * 2014-08-19 2016-02-25 The Children's Hospital Of Philadelphia Compositions and methods for modulating immune response
MX2017002205A (es) 2014-08-19 2017-08-21 Novartis Ag Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
RU2021118125A (ru) * 2014-12-29 2022-04-06 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3711488A1 (en) 2015-05-06 2020-09-23 Snipr Technologies Limited Altering microbial populations & modifying microbiota
CA2992551A1 (en) 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
JP2018534264A (ja) * 2015-09-28 2018-11-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 自己免疫および同種免疫への治療的介入としてのキメラ抗原受容体（ｃａｒ）ｔ細胞
MY196631A (en) * 2015-10-13 2023-04-24 Eureka Therapeutics Inc Antibody Agents Specific for Human Cd19 and uses Thereof
WO2017093969A1 (en) 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
EP4643874A3 (en) 2015-12-22 2026-02-11 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
JP7062640B2 (ja) * 2016-07-29 2022-05-06 ジュノー セラピューティクス インコーポレイテッド 抗ｃｄ１９抗体に対する抗イディオタイプ抗体
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer
KR20190090390A (ko) * 2016-11-30 2019-08-01 인트렉손 코포레이션 스테로이드 투여 및 면역요법
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
ES2912408T3 (es) 2017-01-26 2022-05-25 Novartis Ag Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
AU2018351050B2 (en) 2017-10-18 2025-09-18 Novartis Ag Compositions and methods for selective protein degradation
US12539308B2 (en) 2018-01-08 2026-02-03 The Trustees Of The University Of Pennsylvania Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
CA3107383A1 (en) * 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
US12516099B2 (en) 2018-08-09 2026-01-06 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
EP3844287B1 (en) 2018-08-31 2024-05-22 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2021042060A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
EP4065157A1 (en) 2019-11-26 2022-10-05 Novartis AG Cd19 and cd22 chimeric antigen receptors and uses thereof
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
WO2021142305A2 (en) * 2020-01-10 2021-07-15 Coimmune, Inc. Methods of treating tumors
CN116529266A (zh) 2020-08-31 2023-08-01 耶鲁大学 用于将核酸递送到细胞的组合物和方法
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
EP4602078A2 (en) 2022-10-11 2025-08-20 Yale University Compositions and methods of using cell-penetrating antibodies
JP2025540052A (ja) 2022-12-01 2025-12-11 イェール ユニバーシティー 細胞内ペイロード送達用刺激応答性トレースレス操作プラットフォーム
EP4574838A1 (en) 2023-12-21 2025-06-25 Vilnius University Chimeric antigen receptor (car) with enhanced recruitment of signaling partners

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520587A (ja) * 2004-11-17 2008-06-19 アンジオゲン ファーマシューティカルズ ピーティーワイ リミテッド Ｂ細胞の機能調節のための方法
JP2008523793A (ja) * 2004-12-15 2008-07-10 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ Ｂ型リンパ球様造血増殖に対する細胞傷害性抗体
WO2010102276A2 (en) * 2009-03-06 2010-09-10 Medimmune, Llc Humanized anti-cd19 antibody formulations
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE338124T1 (de) * 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
EP1795588A1 (en) * 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
ES2724451T3 (es) * 2010-02-04 2019-09-11 Univ Pennsylvania ICOS regula fundamentalmente la expansión y la función de linfocitos Th17 humanos inflamatorios
US9233125B2 (en) * 2010-12-14 2016-01-12 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing T cells and methods of treating cancer
US20150290244A1 (en) * 2012-07-13 2015-10-15 The Trustees Of The University Of Pennsylvania Use of cart19 to deplete normal b cells to induce tolerance

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520587A (ja) * 2004-11-17 2008-06-19 アンジオゲン ファーマシューティカルズ ピーティーワイ リミテッド Ｂ細胞の機能調節のための方法
JP2008523793A (ja) * 2004-12-15 2008-07-10 ラボラトワール、フランセ、デュ、フラクショヌマン、エ、デ、ビオテクノロジ Ｂ型リンパ球様造血増殖に対する細胞傷害性抗体
WO2010102276A2 (en) * 2009-03-06 2010-09-10 Medimmune, Llc Humanized anti-cd19 antibody formulations
WO2011059836A2 (en) * 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
WO2012079000A1 (en) * 2010-12-09 2012-06-14 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAVID L PORTER等: "Chimeric Antigen Receptor Therapy for B-cell Malignancies", 《JOURNAL OF CANCER》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109328230A (zh) * 2016-04-15 2019-02-12 宾夕法尼亚大学董事会 嵌合同种异体抗原受体t细胞的组合物和方法
WO2021129015A1 (zh) * 2019-12-27 2021-07-01 昭泰英基生物医药（香港）有限公司 工程化免疫杀伤细胞、其制备方法和应用

Also Published As

Publication number Publication date
EA034644B1 (ru) 2020-03-02
EA201992742A3 (ru) 2020-12-30
JP2015523386A (ja) 2015-08-13
JP2018135363A (ja) 2018-08-30
MX2015000433A (es) 2016-04-28
BR112015000657A8 (pt) 2018-01-16
BR112015000657B1 (pt) 2023-12-05
ES2835232T3 (es) 2021-06-22
US20240261328A1 (en) 2024-08-08
EA201590209A1 (ru) 2015-08-31
EP2872184A4 (en) 2016-03-30
AU2018203756B2 (en) 2019-10-24
KR20150030750A (ko) 2015-03-20
WO2014012001A3 (en) 2015-04-23
AU2020200315A1 (en) 2020-02-06
CN120393001A (zh) 2025-08-01
WO2014012001A2 (en) 2014-01-16
AU2013289984A1 (en) 2015-01-22
MX382772B (es) 2025-03-11
JP2025129358A (ja) 2025-09-04
EP2872184A2 (en) 2015-05-20
AU2020200315B2 (en) 2021-11-04
CA2876734A1 (en) 2014-01-16
US20150290244A1 (en) 2015-10-15
MX2018009820A (es) 2022-08-24
KR102216083B1 (ko) 2021-02-17
JP2020158541A (ja) 2020-10-01
US20180271907A1 (en) 2018-09-27
IN2015DN00139A (2) 2015-06-12
JP2022173331A (ja) 2022-11-18
BR112015000657A2 (pt) 2017-06-27
EA201992742A2 (ru) 2020-09-30
EP2872184B1 (en) 2020-09-16
AU2013289984B2 (en) 2018-03-08
AU2018203756A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US20240261328A1 (en) Use of cart19 to deplete normal b cells to induce tolerance
US20260115284A1 (en) Toxicity management for anti-tumor activity of cars
JP2024056708A (ja) 癌を治療するためのキメラ抗原受容体改変ｔ細胞の使用
JP7372728B2 (ja) 改変ｔ細胞に関する方法および組成物
EP2904106A2 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
US12427181B2 (en) T-cell therapy method
CN108138148A (zh) T细胞的激活和扩增
WO2021244654A1 (en) Activation induced cytokine production in immune cells
US20230226181A1 (en) GENETIC ENGINEERING OF gamma delta T CELLS FOR IMMUNOTHERAPY
WO2022007784A1 (en) Methods of reducing graft rejection of allogeneic cell therapy
KR20220095228A (ko) 암의 t 세포 치료를 위한 세포독성 효과기 기억 t 세포를 생산하는 방법
EA046588B1 (ru) Применение cart19 для лечения или предотвращения реакции "трансплантат против хозяина" (gvhd)

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902

RJ01 Rejection of invention patent application after publication